Johnson & Johnson announced Tuesday that will resume the distribution of its vaccine for COVID-19 in Europe after the European Union medical regulator approved it but with a safety warning, according to Reuters.
The European Medicines Agency (EMA) recommended adding a warning about rare blood clots with low blood platelet count to the vaccine product label, citing that the benefits of injecting a dose outweigh its risks.
Johnson & Johnson Chief Scientific Officer Paul Stoffels said: “This is an extremely rare event. We hope that by raising awareness and putting into practice a clear diagnostic and therapy guide, we can restore confidence in our vaccine. “
Johnson & Johnson said it would honor its commitments to send 200 million doses to Europe and 100 million to the United States.
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
